- Ngoi ra, bn cng nn lu v vn bo qun sn phm ng cch, sn phm lun trong tnh trng tt nht s gip cho cng dng ca n c pht huy mt cch ti a
This is a wellness product and not a medical product, however, consideration should be given to this patch which could potentially be used to mitigate early bone loss
Because the delicate cysteine residues in whey can be easily destroyed by heat and heavy processing, utilizing a high-quality, carefully filtered WPI ensures that these precursors survive digestion and enter the bloodstream intact
Oral BPC-157 capsules Standard oral capsules: Contains BPC-157 powder Take on empty stomach Lower bioavailability (only small amount absorbed) Works directly on stomach/gut lining as it passes through Dosing: 500-1,000mcg daily (higher than injectable due to poor absorption) Split into 1-2 doses Take 30 minutes before meals Best for: Stomach ulcers IBS and digestive issues Leaky gut Esophageal issues Oral stable BPC-157 (Arginate or Acetate) Better oral absorption: BPC-157 Arginate or BPC-157 Acetate Modified to resist stomach acid breakdown Higher bioavailability than standard oral More expensive Dosing: 250-500mcg daily (similar to injectable) Can work systemically when absorbed Still best for gut issues How to take: Empty stomach preferred 30 minutes before food With water Don't take with acidic beverages Sublingual administration (under tongue) Some users try sublingual: Hold under tongue for 60-90 seconds May improve absorption vs swallowing No definitive evidence it's better Worth trying if you have capsules How to do it: Open capsule Pour powder under tongue Hold as long as possible Swallow saliva after 60-90 seconds BPC-157 dosing protocols by condition How much to take depends on what you're treating
Patients who use MaxGXL have seen a reduction in general osteoarthritis by 30-60% and a reduction in autoimmune inflammatory diseases by as much as 75%, along with the beneficial side effects of increased energy and mental clarity
Shimizu K, Kaira K, Tomizawa Y, Sunaga N, Kawashima O, Oriuchi N, Tominaga H, Nagamori S, Kanai Y, Yamada M, Oyama T, Takeyoshi I (2014) ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer
